Article Search
닫기

Microbiology and Biotechnology Letters

보문(Article)

View PDF

Enzymes and Bioactive Compounds

Microbiol. Biotechnol. Lett. 2015; 43(4): 336-342

https://doi.org/10.4014/mbl.1509.09002

Received: September 1, 2015; Accepted: December 1, 2015

Euptelea pleiosperma 에탄올 추출물의 항비만 활성

Anti-Obesity Activity of Euptelea Pleiosperma Ethanol Extract

Jung Ae Park 1, Kyong-Suk Jin 1, Hyun Ju Kwon 1, 2 and Byung Woo Kim 1, 2*

1Blue-Bio Industry Regional Innovation Center, Dong-Eui University, Busan 47340, Republic of Korea, 2Department of Life Science and Biotechnology, College of Natural Science and Human Ecology, Dong-Eui University, Busan 47340, Republic of Korea

Previously, Euptelea pleiosperma was identified as one of the useful sources containing anti-oxidative and anti-inflammatory activities for the first time in our research group. In this study, anti-obesity effect of E. pleiosperma ethanol extract (EPEE) was evaluated by using a pancreatic lipase enzyme inhibition assay and a cell culture model system. EPEE suppressed effectively pancreatic lipase enzyme activity dose dependently. Furthermore, EPEE significantly suppressed adipocyte differentiation, lipid accumulation, triglyceride contents, and triggered lipolysis activity on 3T3-L1 preadipocytes in a dose-dependent manner without cytotoxicity. Anti-adipogenic effect of EPEE was modulated by cytidine-cytidine-adenosine-adenosine-thymidine (CCAAT)/ enhancer binding proteins α (C/EBPα), C/EBPβ and peroxisome proliferator-activated receptor γ (PPARγ) gene and protein expressions. Taken together, these results provide the important new insight that E. pleiosperma possesses anti-obesity activities such as pancreatic lipase inhibition, anti-adipogenic, and lipolysis effects. It might be utilized as promising sources in the fields of nutraceuticals. The identification of active compounds that confer anti-obesity activity of EPEE might be needed.

Keywords: Euptelea pleiosperma, anti-obesity activity, lipase inhibition activity, anti-adipogenic and lipolysis effects

  1. Ali AT, Hochfeld WE, Myburgh R, Pepper MS. 2013. Adipocyte and adipogenesis. Eur. J. Cell Biol. 92: 229−236.
    Pubmed CrossRef
  2. Avram MM, Avram AS, James WD. 2007. Subcutaneous fat in normal and diseased states 3. Adipogenesis: from stem cell to fat cell. J. Am. Acad. Dermatol. 56: 472−492.
    Pubmed CrossRef
  3. Berry R, Jeffery E, Rodeheffer MS. 2014. Weighing in on adipocyte precursors. Cell Metab. 19: 8−20.
    Pubmed KoreaMed CrossRef
  4. Bray GA. 2007. Medical therapy for obesity-current status and future hopes. Med. Clin. North Am. 91: 1225−1253.
    Pubmed CrossRef
  5. Cao Z, Umek RM, McKnight SL. 1991. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 5: 1538−1552.
    Pubmed CrossRef
  6. Chadt A, Scherneck S, Joost HG, Al-Hasani H. 2000. Molecular links between Obesity and Diabetes: “Diabesity”.
  7. de la Garza AL, Milagro FI, Boque N, Campion J, Martinez JA. 2011. Natural inhibitors of pancreatic lipase as new players in obesity treatment. Planta Med. 77: 773−785.
    Pubmed CrossRef
  8. Fock KM, Khoo J. 2013. Diet and exercise in management of obesity and overweight. J. Gastroenterol. Hepatol. 28(Suppl. 4):59−63.
    Pubmed CrossRef
  9. Guo L, Li X, Tang QQ. 2015. Transcriptional regulation of adipocyte differentiation: a central role for CCAAT/enhancerbinding protein (C/EBP) beta. J. Biol. Chem. 290: 755−761.
    Pubmed KoreaMed CrossRef
  10. Haslam D. 2007. Obesity: a medical history. Obes. Rev. 8(Suppl. 1): 31−36.
    Pubmed CrossRef
  11. Jin KS, Park JA, Lee JY, Kang JS, Kwon HJ, Kim BW. 2014. Anti-oxidative and anti-inflammatory activities of Euptelea pleiosperma ethanol extract. Korean J. Microbiol. Biotechnol. 42:170−176.
    CrossRef
  12. Joo JK, Lee KS. 2014. Pharmacotherapy for obesity. J. Menopausal Med. 20: 90−96.
    Pubmed KoreaMed CrossRef
  13. Kakkar AK, Dahiya N. 2015. Drug treatment of obesity: current status and future prospects. Eur. J. Int. Med. 26: 89−94.
    Pubmed CrossRef
  14. Lane MD, Tang QQ, Jiang MS. 1999. Role of the CCAAT enhancer binding proteins (C/EBPs) in adipocyte differentiation. Biochem. Biophys. Res. Commun. 266: 677−683.
    Pubmed CrossRef
  15. Liu F, Kim J, Li Y, Liu X, Li J, Chen X. 2001. An extract of Lagerstroemia speciosa L. has insulin-like glucose uptakestimulatory and adipocyte differentiation-inhibitory activities in 3T3-L1 cells. J. Nutr. 131: 2242−2247.
    Pubmed
  16. Manulu MS, Sutanegara IN. 2006. Pathogenesis and pharmacologic treatment of obesity: the role of energy regulatory mechanism. Acta Med. Indones. 38: 42−50.
    Pubmed
  17. Ntambi JM, Young-Cheul K. 2000. Adipocyte differentiation and gene expression. J. Nutr. 130: 3122S−3126S.
    Pubmed
  18. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, et al. 2002. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 16: 22-26.
    Pubmed KoreaMed CrossRef
  19. Sorisky A. 1999. From preadipocyte to adipocyte: differentiationdirected signals of insulin from the cell surface to the nucleus. Crit. Rev. Clin. Lab. Sci. 36: 1−34.
    Pubmed CrossRef
  20. World Health Organization 2015. Obesity and overweight. Fact sheet N°311. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 28 August 2015.
  21. Zhang WL, Zhu L, Jiang JG. 2014. Active ingredients from natural botanicals in the treatment of obesity. Obes. Rev. 15:957−967.
    Pubmed CrossRef

Starts of Metrics

Share this article on :

Related articles in MBL

Most Searched Keywords ?

What is Most Searched Keywords?

  • It is most registrated keyword in articles at this journal during for 2 years.